Reed Elsevier PLC
13 July 2004
13 July 2004
News release
Issued on behalf of Reed Elsevier PLC and Reed Elsevier NV
Reed Elsevier announces appointment of Chief Executive Officer for Science &
Medical Division
Reed Elsevier Group plc today announced the appointment of Erik Engstrom as
chief executive officer of Elsevier, its global scientific and medical
publishing division.
Mr Engstrom will join the company in August 2004 and will be based in Amsterdam.
He will be a main board director of Reed Elsevier Group plc reporting to Sir
Crispin Davis, Reed Elsevier's chief executive officer.
Mr Engstrom (41), who is Swedish, has been based in the US for the past 18
years. He joins Reed Elsevier from General Atlantic Partners, a private equity
firm, where he was a general partner leading their media and consumer investment
sector since 2001. Prior to that, Mr Engstrom had extensive experience in the
publishing sector as president and chief operating officer of Random House Inc,
the leading global consumer books publishing business of Bertelsmann. He was
also president and chief executive officer of Bantam Doubleday Dell before its
merger with Random House. Mr Engstrom began his business career as a consultant
with McKinsey after gaining his MBA from Harvard Business School where he was a
Fulbright Scholar.
Commenting on the announcement, Sir Crispin Davis said: 'I am delighted to
welcome Erik to Reed Elsevier. He is an exceptionally talented executive with a
consistent track record of success, wide international experience, and extensive
publishing expertise. He will bring strong leadership to the Elsevier
business'.
On joining Reed Elsevier, Mr. Engstrom will be appointed to the Boards of Reed
Elsevier PLC and Reed Elsevier Group plc and will be put forward for election to
the Executive Board of Reed Elsevier NV at the annual general meeting of that
company in 2005.
Mr Engstrom has no details to disclose under paragraph 6.F (b) to (g) of the UK
Listing Rules.
-ends-
For further information please contact:
Susanna Smart, Reed Elsevier, tel +44 (0) 20 7166 5670
www.reedelsevier.com
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.